{"name":"Novartis Gene Therapies","slug":"novartis-gene-therapies","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AVXS-101","genericName":"AVXS-101","slug":"avxs-101","indication":"Spinal muscular atrophy","status":"phase_1"},{"name":"Onasemnogene Abeparvovec-xioi","genericName":"Onasemnogene Abeparvovec-xioi","slug":"onasemnogene-abeparvovec-xioi","indication":"Spinal muscular atrophy (SMA) in pediatric patients","status":"marketed"}]}],"pipeline":[{"name":"AVXS-101","genericName":"AVXS-101","slug":"avxs-101","phase":"phase_1","mechanism":"Gene therapy for spinal muscular atrophy","indications":["Spinal muscular atrophy"],"catalyst":""},{"name":"Onasemnogene Abeparvovec-xioi","genericName":"Onasemnogene Abeparvovec-xioi","slug":"onasemnogene-abeparvovec-xioi","phase":"marketed","mechanism":"Onasemnogene abeparvovec-xioi is a gene therapy that delivers a functional copy of the SMN1 gene via an adeno-associated virus vector to restore survival motor neuron protein production in patients with spinal muscular atrophy.","indications":["Spinal muscular atrophy (SMA) in pediatric patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOUnItUGJRQ1V3MjVuZGpJcXJPTFhmMkd2ZnlDcC1UNmVXb3hpZ0FpcXpBakpzM3ZBUGR1QTFZOHJSZ3M4SmFuZHZGamk5UEdENTFuMTRCUURJWEZoZnRMd1JkRWhIdklLU2JqZFNxZGozYXA1YUNiYmlNUjFNOWpmaFE0eHhiU05jZjBxdE85SDYtVGFuaWVXSnU4SWRqRDA4NTdaRElaSHhkbjZfQnY2T05sZ0R3SkdGbnJRaDlMaTFvd1NMSG8xTTAyX0NkWXM3cUpXeW16OW8xeGFMcnM0OTFEZmx0Q3FLRjd1RkRTZG5sVEFiSW9jRFlyN04?oc=5","date":"2025-12-17","type":"pipeline","source":"Community Impact | News","summary":"Denton officials move forward with development plans for $280M Novartis Gene Therapies plant - Community Impact | News","headline":"Denton officials move forward with development plans for $280M Novartis Gene Therapies plant - Community Impact | News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPZGE5aTN1Q25zYmFBOEk2Z1AxbG5zdUF6bUluXzlHTFNJWDFtRXNhTjZpdUZmazJtWmJOVHJXZzcwZHBLYmJiNFZxTkwzM0EweVMxOG4tT2xfVFltOENqS19TT0F6dE5MY1VOVzFUVmxoQVJFZVlOa2NjRVpVb25sV3hXd1BNZ3hvdm1RblRjQy01Qnh6aGgwUmZEd2ZsVFNsOVU3ak1ZdmI3Qk5vYmNycXo2bzNvTlZfV08zVHpiWFJuUGRCdFE?oc=5","date":"2025-11-25","type":"regulatory","source":"Reuters","summary":"US FDA approves Novartis' gene therapy for rare muscle disorder - Reuters","headline":"US FDA approves Novartis' gene therapy for rare muscle disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQOUtzZ0xxdGFrbjFPUU9tbDNvR0lNa09IY1ZGYUx3MjRmWnJCZ2xpWE83T0V5bHFkS1dHTXpmLU1tbGNJUWJJSThyVUpUM2N3dmgyaGFFb05VZzRoT0tzbnBHNUdFVmtqUVozQm5UcHRuRmZuTmdwakF5ZDJMbnhzVmZWMjZ1Y3hicU5Kd2Nvb3RaajZnZUVMc2Z2TmpuWUZhczZ6cjRvREo?oc=5","date":"2025-11-25","type":"regulatory","source":"Fierce Pharma","summary":"Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M - Fierce Pharma","headline":"Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQSEJ5TEtacGhNNG1hT0FvVmc2MjlZYWh2RWRqa0o2WHpSR2ZlVmVfcEpwaEQzNEZpYk1lenVLMWNEQU5wa3pqdEk3bkNxSjNlR2lFSTV1ZG9BTzBtMVZDYXppaGZfdUJDLWkzMlNua05Pa3VwRVpLVWFFSFJ2emZhVDFJMmg4aFRHUF9PcDloZ1ZNNEVETVhfTUZETHQtZkloajdjaUhHSlZfdUtYdjI4RGdUWQ?oc=5","date":"2025-11-25","type":"regulatory","source":"BioPharma Dive","summary":"Novartis wins approval to use SMA gene therapy in older patients - BioPharma Dive","headline":"Novartis wins approval to use SMA gene therapy in older patients","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOdmc4bklzZnJNbG1KclBsbVpBXzd6aUl3dDVTcEY2bHhtV19pTGxsUE9MRmdrWjNGR2Q5QXdtaEJjYlpuOE15WUZLN0VfdGFvYVFES202bUdLWmlFdzZFNWxhMmIzSjZYVGI0R3dWQVRsb0hqT0pCQWhQT3Rmd0gwZWRYTTVXYmZwMjQyZmI1bW5Cd1hzZ3dRaURzeWp3dnFmRmF5Z0ZoME90RmpkdUotX3czSjROWVZxeEE?oc=5","date":"2025-11-25","type":"regulatory","source":"BioSpace","summary":"Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight - BioSpace","headline":"Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQaEt4eG5FSkpkWmhWd0l1eU9PSmU2QTVIZzhTM2NSTm1OU0NKd1N3bGZxejV5b2xmSFozR3oxbEpXZjFKQTF5UHNIdUUwVTVydkpiSzZZTWFEUzFVVzZTWGxEV1lKWTVqQjVaWlhwcElLUTVIOWdFSk00eG5MWHhVY1dB?oc=5","date":"2025-11-25","type":"pipeline","source":"pharmaphorum","summary":"Novartis' SMA gene therapy cleared for wider use in US - pharmaphorum","headline":"Novartis' SMA gene therapy cleared for wider use in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9KcEIybzFkQ0VEUnd3OGNSTVp3UHpRSDRhNGZoU3Q5clBNZ1NoTFM5VTFsY2JsWTBLU2pXTjMtN0d4bkUyNEtVY083dzB5ZHVXS3Zz?oc=5","date":"2025-11-24","type":"regulatory","source":"FirstWord Pharma","summary":"New formulation of Novartis' SMA gene therapy gets FDA green light, $2.59M price tag - FirstWord Pharma","headline":"New formulation of Novartis' SMA gene therapy gets FDA green light, $2.59M price tag","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOYTlNNHgzRFhwYWFaaVc0dEVHbnZEc1pmd1ZtdGl4dHhPWkZLcWY0dGxoS0tWUkVtbFIyeXRVaU1mcEVpdFhHT0VwSzRzZVM3VjUtQ2tXQ0pHTnVhcXMxaWpzMzJDRWZuXzlqakVkVnRjNmtQbkwzTmxXblNLVkZsMFZ5NTV1VWhwTGVuY3VkYk1yUkJ6RzJidGpfelRWUU5YeG50MUdWTnlSdmZicVNmRE85UDEtTjNWVWJqSGd5T2pldUFkMmRIempiaVI1ckV4QnBaSlV6OVI4bHZfWEl6ZDV3?oc=5","date":"2025-11-20","type":"pipeline","source":"Pharmaceutical Online","summary":"Novartis To Add Small Molecule & Fill/Finish Capacity With North Carolina Drug Manufacturing Investments - Pharmaceutical Online","headline":"Novartis To Add Small Molecule & Fill/Finish Capacity With North Carolina Drug Manufacturing Investments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQSG84VjkzeXJjeEpxMjlqM1BBVGxmVEJVUGZGZGNxdndLaDFZSzl1Tko0ZE44MHZqYnpTVWl2N3A3dW1YdkUyN1F3OEE2TDFhRDBOcHVoQnBlRjJ3TlhadGMzSUVvMURRSVl4WU95LS1NVlZSalVDRmJYQmZNX3VqVGhR?oc=5","date":"2025-11-19","type":"pipeline","source":"WRAL","summary":"1,700 jobs slated for Triangle through pharmaceutical, financial companies - WRAL","headline":"1,700 jobs slated for Triangle through pharmaceutical, financial companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNMmNJT09qTU9JRnJYaFVnRV9tbFkyN3NLLUZ4M3ZteHRtQmV3dkNqRDUwbUFtTFpUOEQwMHZaTHlHTl9fUkFFMnVyVVFFSlB1M2RUZDVYakJhY0RUeWk5dzh2cnkxZ2JhWFgwSEhqYjY4emZhS29BR01ZU2xVdWx4dTNtYkE4c2pxZ0hDVEh3?oc=5","date":"2025-11-18","type":"pipeline","source":"The Business Journals","summary":"Swiss pharma giant Novartis considers $280 million manufacturing plant in Denton - The Business Journals","headline":"Swiss pharma giant Novartis considers $280 million manufacturing plant in Denton","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNY0xZWUItZzcwb3J5OEFyd3l1WWhKSE84dFZJN0drYTN4QXN3Zno5d1B1TDlUMmdmOWQzTDIyclM0Y1F5MnJYbG1ZdTRZZlFhb3Jmem14RzcwZlkwOXVnQWZsaURwTXliQWNDbVp3aFdtY3FwT01xQlhaSUZwXzByQkNXUDd5alg1c09zU2prbzREQWJ1cFpqS1JLdzNYX0RvZkd3SE42T0hIZ2lXektpSk5vaTk0NXZmWHdtWEhzSTk0OFZUeFE?oc=5","date":"2025-10-09","type":"pipeline","source":"Citeline News & Insights","summary":"Big Pharma Still Sees Value In Cell And Gene Therapy’s Next Wave - Citeline News & Insights","headline":"Big Pharma Still Sees Value In Cell And Gene Therapy’s Next Wave - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOdGt6bGNjeTM2V01FQW9RNWRONTZuWTZQOWtzYkc3bGhJdmtqTFZMWDF3cnlGYS1tSHlVNmJxcW9DdWI1Z0hMenN0bm9wbUUzcFFVSEFMUjE2NGVTVWpZLVdFUzluanNXTzRwWWJ4UFpSb19mMmI1dkpSMjc0MHRITzY3RUZHSm9iZkszTU5HbTFPSEFOeXpLN2JjQXhpeWM?oc=5","date":"2025-07-22","type":"pipeline","source":"Pharma Voice","summary":"Novartis’ Zolgensma sales fall again as gene therapy market woes persist - Pharma Voice","headline":"Novartis’ Zolgensma sales fall again as gene therapy market woes persist","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}